James E. Thomas

James is a co-founder of Thomas, McNerney & Partners and has been investing in health care companies since 1992.

James previously headed Warburg Pincus LLC's medical technology private equity practice, where he had responsibility for investments in biotechnology, pharmaceutical, medical device and diagnostic companies. Historical investments include: American Medical Systems Holdings, Inc. (AMMD), Coley Pharmaceutical Group, Inc. (COLY sold to Pfizer), The Medicines Company (MDCO), NeXagen, Inc. (NXGN/NXTR sold to Gilead Sciences, Inc.), OsteoBiologics, Inc. (sold to Smith & Nephew plc), Oxford GlycoSciences, plc (OGSI sold to Celltech Group plc), Transkaryotic Therapies, Inc. (TKTX sold to Shire Pharmaceuticals Group plc), Visible Genetics, Inc. (VGIN sold to Bayer Corporation), Wright Medical Group, Inc. (WMGI), and Xomed Surgical Products, Inc. (XOMD sold to Medtronic, Inc.).

He is currently a board member of CAS Medical Systems, Inc. (CASM), Clarus Therapeutics, Inc., Galil Medical Ltd., InnoPharma, Inc., Keystone Dental, Inc. and Packaging Coordinators, Inc.

James E. Thomas is the Partner at Thomas, McNerney & Partners, based in United States, North America. With a background in Venture Capital, James E. Thomas has a rich history of leadership and innovation. James E. Thomas studied BS Finance, Economics @ Wharton School of the University of Pennsylvania. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.